Bioprocessing
BioNTech, InstaDeep form AI lab
BioNTech and InstaDeep will form a joint artificial intelligence (AI) lab as part of a multiyear strategic collaboration.
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity efforts, including COVID-19 vaccine infrastructure.
ReiThera touts phase I COVID-19 vaccine results
ReiThera is highlighting positive phase I clinical trial results for its COVID-19 vaccine candidate, GRAd-COV2.
Capricor begins phase II trial of COVID-19 cell therapy
Capricor Therapeutics has begun a phase II trial of its CAP-1002 cell therapy for patients with severe COVID-19 disease.
City of Hope initiates SARS-CoV-2 vaccine phase I trial
The City of Hope has begun a phase I clinical trial of COH04S1, which is its investigational SARS-CoV-2 vaccine, in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
MediciNova begins producing vector for its intranasal COVID-19 vaccine
MediciNova has begun good manufacturing practice-based master virus seed stock production of its novel intranasal SARS-CoV-2 vaccine for COVID-19.
Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.
Minaris to manufacture Mustang Bio's lentiviral gene therapy in Europe
Minaris Regenerative Medicine has signed an agreement with Mustang Bio to enable technology transfer and good manufacturing practice clinical manufacturing of Mustang's MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency.
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals
Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals over the past week have included an orphan drug designation for a new gene therapy, as well as approvals for a quadrivalent flu vaccine and a hepatitis B vaccine.
AstraZeneca COVID-19 vaccine achieves 70% efficacy
AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating it met the primary endpoint of preventing COVID-19.
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter